Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced it has received ethical approval from the Cancer Institute and Hospital at the Chinese Academy of Military Science to conduct a Phase I/II clinical study (CT-3505-I-01) of its CT-3505 in patients with ALK-positive non-small cell lung cancer (NSCLC).
Drug Profile
CT-3505, an in-house developed third-generation ALK inhibitor, received clinical trial approval in July 2019. It is the first drug of its kind in China to target NSCLC patients resistant to first- and second-generation ALK inhibitors.
Global Landscape
Currently, the only third-generation ALK inhibitor available globally is Pfizer’s Lorbrena (lorlatinib). A Phase I study of Lorbrena in 62 patients demonstrated a favorable safety profile, good pharmacokinetics, and anti-tumor activity in drug-resistant patients.-Fineline Info & Tech
